Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial

Abstract

Introduction and purposeSarcopenia is defined as a decrease in muscle mass and muscle strength, and it has been demonstrated to be an adverse predictor in numerous types of cancers. Exercise therapy (ET) carries multiple health benefits in several diseases. Despite these clinical benefits, there are limited data available regarding patients with pancreatic cancer (PC) undergoing ET. We aim to prospectively examine the effect of ET on sarcopenia in patients with PC.Methods and analysisAll clinical stages of PC can be included. When registering study subjects, a precise evaluation of the nutritional status and the daily physical activities performed will be undertaken individually, for each participant. Study participants will be randomly allocated into two groups: (1) the ET and standard therapy group and (2) the standard therapy group. Amelioration of sarcopenia at 3 months postrandomisation will be the primary endpoint. Muscle mass will be calculated using bioimpedance analysis. Sarcopenia will be defined based on the current Asian guidelines. Participants will be instructed to perform exercises with>3 metabolic equivalents (mets; energy consumption in physical activities/resting metabolic rate) for 60 min/day and to perform exercises with>23 mets/week. In the ET group, physical activities equal to or greater than walking for 60 min/day will be strongly recommended.Ethics and disseminationThe Institutional Review Board at Hyogo College of Medicine has approved this study protocol (approval no. 2772). The final data will be publicly announced. A report releasing the study results will be submitted for publication.Trial registration numberUMIN000029271; Pre-results.

Declaración de consenso de la organización ejercicio y ciencias del deporte – Australia: el ejercicio como medicina en el manejo del cáncer

“…Actualmente, existe evidencia de mayor o menor fuerza acerca de la seguridad, factibilidad o eficacia del ejercicio a lo largo de todas las etapas de cáncer en un amplio espectro de tipos de esta enfermedad, incluyendo las formas más comunes como cáncer de mama (Hayes et al, 2013), próstata (Crawford-Williams et al, 2018), colorrectal (Devin et al, 2018) y de pulmón (Edvardsen et al, 2015), aunque sin limitarse a ellos; también, se incluyen otros tipos, como el hematológico (Wiskemann et al, 2011), de cabeza y cuello (Jackson et al, 2018), cáncer infantil y adolescente (Morales et al, 2018) así como ginecológico (Zhou et al, 2017;Basen-Engquist et al, 2014). Además, tipos menos comunes como cáncer cerebral (Capozzi et al, 2016), testicular (Adams et al, 2017) y del páncreas (Yoh et al, 2018). Algunos estudios se han concentrado específicamente en cohortes de pacientes con enfermedad más avanzada (Dittus et al, 2017;Heywood et al, 2018), lo cual ofrece evidencia preliminar que va más allá de los pacientes con enfermedad en etapas tempranas, a quienes generalmente se les considera que están 'bien'.…”